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Background: The risk of pancreatic cancer, the 4th deadliest cancer for both men and women in the United States,
is increased by obesity. Calorie restriction (CR) is a well-known dietary regimen that prevents or reverses obesity
and suppresses tumorigenesis in a variety of animal models, at least in part via inhibition of mammalian target of
rapamycin (mTOR) signaling. Branched-chain amino acids (BCAA), especially leucine, activate mTOR and enhance
growth and proliferation of myocytes and epithelial cells, which is why leucine is a popular supplement among
athletes. Leucine is also increasingly being used as a treatment for pancreatic cancer cachexia, but the effects of
leucine supplementation on pancreatic tumor growth have not been elucidated.
Results: Supplementation with leucine increased pancreatic tumor growth in both lean (104 ± 17 mm3 versus
46 ± 13 mm3; P <0.05) and overweight (367 ± 45 mm3 versus 230 ± 39 mm3; P <0.01) mice, but tumor
enhancement was associated with different biological outcomes depending on the diet. In the lean mice, leucine
increased phosphorylation of mTOR and downstream effector S6 ribosomal protein, but in the overweight mice,
leucine reduced glucose clearance and thus increased the amount of circulating glucose available to the tumor.
Conclusions: These findings show that leucine supplementation enhances tumor growth in both lean and
overweight mice through diet-dependent effects in a murine model of pancreatic cancer, suggesting caution
against the clinical use of leucine supplementation for the purposes of skeletal muscle enhancement in
cachectic patients.
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Effective prevention and treatment strategies are urgently
needed for pancreatic cancer, the 4th leading cause of
cancer-related death in both men and women in the
United States [1]. Less than 15% of pancreatic cancer
patients have localized disease amenable to curative re-
section, and the overall 5-year survival rate in affected pa-
tients is less than 5% [2]. Obesity is an established
pancreatic cancer risk and progression factor in humans
and animal models [3-5]. In contrast, calorie restriction
(CR) prevents or reverses obesity and related metabolic* Correspondence: shursting@austin.utexas.edu
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unless otherwise stated.perturbations and pancreatic tumor development and/or
progression in experimental models [6-11]; the impact of
CR on human pancreatic cancer has not been well studied.
CR results in a negative energy balance state and exerts its
antitumor effects, at least in part, through decreased
mammalian target of rapamycin (mTOR) signaling in many
epithelial tissues [7-9,11,12]. mTOR acts as a nutrient
sensor that regulates protein synthesis, cell survival, and
proliferation in response to growth factor levels, nutrient
availability, and intracellular energy status. We have pre-
viously established that rapamycin (a selective mTOR
inhibitor), and metformin (an indirect inhibitor of mTOR
signaling through its effects on gluconeogenesis and asso-
ciated activation of AMPK-regulated signals), partially
mimic the tumor inhibitory effects of CR on transplanted
pancreatic tumor growth [13].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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for over 20% of total dietary protein intake, are known
activators of the mTOR pathway in muscle and epithelial
tissues [14-16]. Of the three BCAAs, leucine exerts the
most potent effect on mTOR activation and enhance-
ment of protein synthesis in various tissues, including
skeletal muscle [17,18]. Athletes commonly use leucine
supplementation to activate mTOR-regulated protein
synthesis and accelerate muscle repair and regeneration
after injuries or intense bouts of exercise [19]. Leucine
supplementation is also increasingly being recommended
to reduce the muscle wasting that occurs with cancer
cachexia [20]. Cachexia is characterized by involuntary
weight loss and muscle wasting, is associated with in-
creased morbidity and mortality, and frequently occurs in
pancreatic cancer patients [21]. Increased muscle protein
synthesis in response to leucine-induced mTOR activation
has been shown to inhibit muscle wasting in mouse
models of cancer cachexia and in cancer patients [22-25].
However, the rates of protein synthesis increase to a much
greater extent in tumors than in muscle [24], suggesting
that while leucine supplementation may protect against
cancer-associated cachexia, it may also enhance the
progression of the cancer.
Unfortunately, studies of the effects of leucine sup-
plementation on cancer are limited. Long-term leucine
supplementation (2% of diet, w/w) promoted bladder
cancer development in rats treated with a known bladder
carcinogen [26,27], but no studies have connected leucine
supplementation with tumor growth. In the present study,
we tested the effect of leucine supplementation on trans-
planted Panc02 mouse pancreatic cancer growth and
mTOR signaling in the context of lean mice (fed a CR diet
regimen) or overweight mice (fed a high calorie control
diet regimen). Our findings suggest that leucine enhances
pancreatic tumor progression in lean and overweight
mice, and the underlying mechanisms may differ by
weight status.
Methods
Mice and dietary interventions
All experiments were conducted under a protocol approved
by the Institutional Animal Care and Use Committee at the
University of Texas at Austin. Eighty-eight male C57BL/6
mice were obtained from Charles River Breeding Labora-
tories (Wilmington, MA, USA) at 6 to 8 weeks of age, and
upon arrival were singly-housed in a semibarrier facility at
the University of Texas at Austin Animal Resource Center
and fed a chow diet during a one-week acclimation period.
Mice were then randomized to receive one of four diets
for 27 weeks: (i) AIN-76A control diet consumed ad
libitum (control, n = 22); (ii) 30% CR diet (CR, n = 22); (iii)
control diet with leucine supplementation (5% of diet, w/
w) consumed ad libitum (control + LEU, n = 22); or (iv)30% CR diet with leucine supplementation (CR + LEU,
n = 22). The AIN-76A control diet, when consumed
ad libitum, results in an overweight phenotype character-
ized by steady weight gain, while the CR results in a lean
phenotype characterized by weight maintenance [28,29].
Both CR diets were administered as a daily aliquot pro-
viding 70% of the total energy but 100% of the vitamins,
minerals, amino acids and fatty acids consumed by the
controls. Leucine was purchased from AIDP, Inc. (City of
Industry, CA, USA) and was incorporated into the AIN-
76A diet premix to provide 50 g/kg feed, or 5% dietary
leucine supplementation. This dose of leucine is com-
monly used in animal studies of muscle regeneration
[30,31]. All diets were purchased from Research Diets
(New Brunswick, NJ, USA).
Energy intakes and body weights for each mouse were
recorded weekly for 21 weeks, and then glucose tolerance
tests (GTTs) were performed on a randomly selected sub-
set of animals (n = 10/group). After injecting a 20% (w/v)
glucose solution, blood glucose levels were measured with
a Contour glucometer (Bayer HealthCare LLC, Mishawaka,
IN, USA) at baseline, 15, 30, 60, and 120 minutes. Also
after the rats were on the diet for 21 weeks, quantitative
magnetic resonance (qMR) analysis (EchoMRI, Houston,
TX) was done on a randomly selected subset of animals
(n = 10/group) to obtain percent body fat and lean
mass. At 22 weeks on the diet, all the mice were
fasted for 12 hours and blood samples were collected from
the retro-orbital venous plexus. After coagulating at room
temperature for 30 minutes, blood samples were centri-
fuged at 9,300 × g for 5 minutes. Serum was separated,
then snap-frozen and stored at −80°C until assayed for
hormones. At 23 weeks on the diet, randomly selected
mice (control, n = 7; control + LEU, n = 6; CR, n = 6; and
CR + LEU, n = 7) were fasted for 12 hours and anes-
thetized by CO2 inhalation. Blood was collected by cardiac
puncture, and pancreata were collected and stored for
analyses other than those outlined in this manuscript.
One mouse from the control + LEU group died, and one
mouse from the CR group died before week 23. All
remaining mice (n = 15/group) were subcutaneously
injected into the right flank with 500,000 Panc02 cells
(kindly provided by Dr. J. Schlom, National Cancer
Institute, Bethesda, MD, USA) suspended in serum-
free McCoy’s 5A medium. Once palpable, tumors were
measured weekly with calipers, and tumor volume was ap-
proximated using the formula for an ellipsoid (4/3πr1
2r2).
At 27 weeks on the diet, mice were fasted for 12 hours
and then anesthetized by CO2 inhalation. They then
underwent cardiac puncture for blood collection and
were subsequently killed by cervical dislocation. Pancreatic
tumors were harvested and either snap-frozen in liquid
nitrogen and stored at −80°C, or fixed with 10% neutral-
buffered formalin overnight, switched to 70% ethanol,
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chemical analyses.
Serum hormones
After study termination, serum insulin and leptin levels
were analyzed using Lincoplex™ bead-based multiplexed
assays (Millipore, Billerica, MA, USA; MADPK-71 K-07).
Serum adiponectin and IGF-1 were quantified by single-
plex assay kits (Millipore; MADPK-71 K-ADPN and
RMIGF187K, respectively). All assays were analyzed using
a BioRad Bioplex™ analyzer (BioRad, Hercules, CA, USA)
according to manufacturer’s directions.
Immunohistochemical analyses
Formalin-fixed tissues were embedded in paraffin, cut
into 4-μm thick sections, and processed for immuno-
histochemistry at the Histology Core Laboratory at The
U.T. M.D. Anderson Cancer Center, Science Park Research
Division (Smithville, TX, USA). Antibodies used for immu-
nohistochemistry were optimized by core personnel using
positive and negative controls for each analysis. Slides
were deparaffinized in xylene and sequentially rehy-
drated in ethanol to water. Endogenous peroxidase activity
was quenched with 3% hydrogen peroxide for 10 minutes.
Antigen retrieval required microwaving slides with
10 mM citrate buffer. Nonspecific binding was blocked by
treating sections with Biocare blocking reagent (Biocare
Medical, Concord, CA, USA) for 30 minutes at room
temperature, followed by incubation with primary anti-
body diluted in blocking buffer overnight at 4°C. The
following primary antibodies and dilutions were used:
phospho-S6 ribosomal proteinS235/236 (Cell Signaling,
Danvers, MA, USA; 1:100); phospho-mTORSer2448
(Cell Signaling; 1:50); phospho-ACCSer79 (Cell Signaling;
1:50); Ki-67 (Dako, Carpinteria, CA, USA; 1:200); cyclin
D1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA;
1:500); and cleaved caspase-3 (R&D Systems, Minneapolis,
MN, USA; 1:500). Slides were washed twice in PBS,
incubated for 30 minutes with secondary antibody,
washed two times with PBS, stained with diaminobenzi-
dine (BioGenex, Fremont, CA, USA) and counterstained
with hematoxylin. Images were captured by the Aperio
ScanScope XT (Aperio Technologies, Vista, CA, USA)
and staining was quantified using the Aperio ImageScope
(Aperio Technologies). For Ki-67, phospho-mTOR, and
cyclin D1 quantification, automated algorithms were used
to determine negative or positive nuclear staining. The
percentage of positive cells was obtained with 20× object-
ive in pancreatic tumor sections. Positive staining was
defined as 1+, 2+, and 3+ for cyclin D1 and phospho-
ACC. Positive staining for phospho-mTOR was defined as
only 2+ and 3+ due to its high baseline phosphorylation.
Cleaved caspase-3 (CC3) was quantified as the average
area of positively stained cells, with positive stainingdefined as at least 70% of a 100 μm× 100 μm section. For
all proteins, the positive staining was averaged per group
(n = 5/group).
In vitro studies
Panc02 cells were cultured in a 37°C incubator under 5%
CO2 with McCoy’s 5A media with glutamine (HyClone,
Logan, UT, USA) and 3 g/L glucose but without BCAA,
and then supplemented with penicillin/streptomycin, non-
essential amino acids, sodium pyruvate, HEPES, 10% heat-
inactivated FBS (HyClone), and physiological levels of
leucine, isoleucine, and valine (MP Biomedicals, Santa
Ana, CA, USA) [32]. For western blotting, approximately
100,000 Panc02 cells were seeded in 6-well plates and
allowed to settle overnight in McCoy’s 5A media with 10%
FBS. Cells were then treated with McCoy’s 5A plus 10%
FBS with or without leucine supplementation and McCoy’s
5A plus 1% FBS with or without leucine supplementation
(MP Biomedicals, Santa Ana, CA, USA). For western blot
analysis, cells were treated for 20 min with 0.3 mM leucine
after 3 hours of media pretreatment.
Western blotting
Panc02 cells were lysed on ice for 1 hour in RIPA buffer
(Sigma, St. Louis, MO, USA) with protease inhibitor
tablet (Roche Applied Sciences, Indianapolis, IN, USA)
and phosphatase inhibitor cocktails II and III (Sigma).
Protein lysates (40 μg) were resolved by SDS-PAGE
using 6%, transferred to PVDF membranes (Bio-Rad,
Hercules, CA, USA) overnight at 25 volts and blocked
for 1 hour at room temperature with LI-COR Blocking
Buffer (LI-COR Biotechnologies, Lincoln, NE, USA).
Membranes were incubated overnight at 4°C with pri-
mary antibody (from Cell Signaling unless otherwise
stated) diluted in 5% BSA (Santa Cruz) and specific for:
phospho-ACCSer79 (1:1000), β-actin (1:10000; Sigma),
phospho-AMPKαT172 (1:1000), cleaved caspase-3 (1:1000),
phospho-mTORSer2448 (1:1000), phospho-p70S6KT389
(1:1000), and phospho-S6 ribosomal proteinSer235/236
(1:1000). β-actin was used as a loading control for all anti-
bodies. After three washes (5 minutes each) in 0.1%
Tween-20/PBS (PBS-T), membranes were incubated for
1 hour at room temperature in species-specific secondary
antibody (LI-COR) diluted (1:5000) in LI-COR Blocking
Buffer. Following two washes in PBS-T and one wash in
PBS, membranes were scanned using the Odyssey infrared
fluorescent imaging system (LI-COR). Densitometry was
performed using LI-COR software (LI-COR). Relative
levels of proteins were calculated from three biological
replicates.
Cell proliferation assay
Cell viability was measured by the 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)
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MD; 4890-025-K). In 96-well plates, Panc02 (1500 cells/
well) in media were allowed to adhere overnight. Each
well was filled with fresh treatment media supplemented
with different amounts of FBS (10% or 1%) and leucine
(0 or 0.3 mM). The cells were then incubated for 24 h at
37°C, exposed to fresh treatment media after the removal
of old media, and incubated for an additional 24 h. MTT
was added at a 1:10 ratio for 2 h, then the liquid was
aspirated and 100 μL of dimethyl sulfoxide (DMSO) was
added to lyse the cells and dissolve the solid residue. The
optical density of each well at 570 nm and 690 nm, a
reference wavelength, was determined using the Synergy 2
Multi-Detection Microplate Reader and Gen5 Data Ana-
lysis Software (Fisher Scientific, Pittsburgh, PA). Relative
cell viability was then calculated using the absorbance of
cells grown in media with 10% FBS and no leucine supple-
mentation for normalization. Data shown represent the
average of three biological replicates.
Statistical analysis
Statistical analyses were conducted using GraphPad
Prism (GraphPad Software, La Jolla, CA). Temporal
differences between groups with respect to body weight
and energy intake were assessed using repeated mea-
sures analysis; final measurements were compared using
one-way ANOVA and Newman-Keul’s post hoc test of
significance. Blood glucose levels at each time point
were compared using one-way ANOVA followed by
Newman-Keul’s post hoc test of significance, and overall
blood glucose differences were compared by performing
a one-way ANOVA on calculated areas under the curve
followed by Newman-Keul’s post hoc test of significance.
Pretumor serum hormone levels, percent body fat, lean
mass, and fasting glucose at week 21 were compared by
one-way ANOVA followed by Newman-Keul’s post hoc
test of significance. Final measurements of ex vivo tumor
volume and immunohistochemical staining of all anti-
bodies were also compared among the groups by one-
way ANOVA followed by Newman-Keul’s post hoc
test of significance. To compare the effects of leucine
supplementation in media with either 10% FBS or 1%
FBS, western blot densitometry and relative cell via-
bilities at their respective time points were compared
by two-tailed t-tests. Results were considered signifi-
cant if P <0.05.
Results
Effects of calorie restriction and leucine supplementation
on body composition, glucose homeostasis, and serum
hormones
Male C57BL/6 mice were fed a control diet with or with-
out leucine supplementation, or a 30% CR diet with or
without leucine supplementation, for 27 weeks (including21 weeks of diet before GTTs and qMRs were performed).
Relative to the control mice, the CR mice had significantly
reduced caloric intake (n = 22/group; P <0.001), body
weight (n = 22/group; P <0.001), body fat (n = 10/group;
P <0.001), and lean mass (n = 10/group; P <0.001), irre-
spective of leucine supplementation (Figure 1A-D).
At 21 weeks of study, the CR group without leucine
supplementation, relative to controls without leucine
supplementation, displayed enhanced glucose clearance
as assessed by GTT (n = 10/group; P <0.05), with blood
glucose concentrations peaking in 15 minutes in CR
mice and 30 minutes in control mice following glucose
bolus (Figure 1E). Leucine supplementation significantly
decreased glucose clearance in the context of the high-
calorie control diet (n = 10/group; P <0.001), but did not
significantly alter glucose uptake in the context of the
CR diet (n = 10/group; P >0.05) (Figure 1E). Even at
6 weeks, leucine supplementation showed the same
trend of inhibiting glucose clearance in mice on the
control diet (see Additional file 1). The CR diet group
without leucine supplementation showed significantly
lower fasting serum glucose levels relative to the con-
trols (control group, n = 14; CR group, n = 15; P <0.001)
(Figure 1F), and leucine supplementation further reduced
glucose levels in the CR mice (n = 15/group; P <0.001),
but did not affect glucose levels in control mice (control
group, n = 14; control group with leucine supplementa-
tion, n = 15; P >0.05).
The CR mice without leucine supplementation, relative
to the control mice without leucine supplementation, had
significantly lower serum levels of IGF-1 (control group,
n = 9; CR group, n = 10; P <0.001) (Figure 1H) and leptin
(control group, n = 9; CR group, n = 10; P <0.001)
(Figure 1I) and higher levels of adiponectin (control
group, n = 9; CR group, n = 10; P <0.001) (Figure 1J)
but did not have significantly altered levels of insulin
(control group, n = 9; CR group, n = 10; in P >0.05)
(Figure 1G). Leucine supplementation lowered IGF-1 in
the control group (n = 9/group; P <0.001) and reduced
adiponectin (n = 10/group; P <0.05) in the CR mice, but
caused no other alterations to the levels of the other
energy-responsive serum hormones measured in either
diet group (Figure 1G-H).
Effects of calorie restriction and/or leucine supplementation
on Panc02 tumor growth and apoptosis
To interrogate whether leucine supplementation modu-
lates murine pancreatic cancer cell growth in control
mice, and/or impacts the anticancer response to CR, we
injected mice from each diet group with Panc02 cells at
week 23 and monitored tumor growth during the next
4 weeks. The final mean ex vivo tumor volume from CR
mice, both with and without leucine supplementation, was
significantly smaller than control mice (n = 14/group;
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Figure 1 Effects of calorie restriction (CR) and/or leucine (LEU) supplementation on body composition glucose tolerance, and
hormones. (A) Caloric intake and (B) body weight of C57BL/6 male mice on control and CR diets with and without leucine supplementation
reported until glucose tolerance test (GTT) and quantitative magnetic resonance imaging (qMRI) performed (21 weeks, n = 22/group; P <0.001
between groups with different letters). (C) qMRI quantification of body fat and (D) lean mass between mice fed control or CR diets with and
without leucine supplementation for 21 weeks (n = 10/group; P <0.001 between all groups with different letters). (E) GTT performed after
21 weeks on diet (n = 10/group; P <0.05 between control and CR, P <0.001 between all other groups with different letters). (F) Fasting glucose
levels after 21 weeks on diet (prior to tumor injection; control, n = 14; all other groups, n = 15) (P <0.001 between all groups with different letters).
(G-J) Serum hormone analyses after 21 weeks on diet (prior to tumor injection) of (G) insulin (P <0.05 between control and CR + LEU), (H) IGF-1
(P <0.001 between groups with different letters), (I) leptin (P <0.001 between control and both CR groups; P <0.01 between control + LEU and
both CR groups), and (J) adiponectin (P <0.001 between CR and both control groups; P <0.05 between all other groups with different letters)
(control groups, n = 9; CR groups, n = 10). All data are presented as the mean with error bars indicating the SD (A,B) or SEM (C-J). Differences are
considered significant if P <0.05. Abbreviations: CON, control diet; CR,calorie restriction diet; LEU, leucine-supplemented diet.
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significantly larger tumors in both the control and CR diet
groups, relative to each diet’s respective nonsupplemented
group (control group and control with leucine supple-
mentation group, n = 14; P <0.01) (CR group, n = 14; CR
group with leucine supplementation, n = 13; P <0.001)
(Figure 2A).
The influence of energy balance and leucine supple-
mentation on cell proliferation was assessed in tumor
tissues by immunohistochemical staining against Ki-67
(Figure 2B). While CR significantly reduced cell prolifer-
ation, relative to control diet, in nonsupplemented mice
(n = 5/group; P <0.001), leucine supplementation signifi-
cantly increased cell proliferation relative to the respective
nonsupplemented mice within both diet groups (n = 5/
group; P <0.001). The amount of Ki-67 staining in the
leucine-supplemented CR group was augmented to theFigure 2 Effects of leucine supplementation on Panc02 tumor growth
control and calorie restriction (CR) diets with and without leucine (LEU) sup
LEU, and CR, n = 14/group; and CR + LEU, n = 13) (P <0.01 between control
groups with different letters). (B) Comparison of immunohistochemical ana
between all groups with different letters) and cleaved-caspase 3 (CC3) (n =
P <0.05 between all other groups with different letters). Scale bars represen
CC3 data are presented as mean ± SEM. Differences are considered signific
diet; LEU, leucine-supplemented diet.level of the nonsupplemented control group (n = 5/group;
P <0.001).
Leucine supplementation in the CR group enhanced
tumor proliferation more than it did tumor burden
(Figure 2A,B), suggesting that final tumor size was
influenced by both proliferation and apoptosis. Based
on immunohistochemical analysis of tumors, we found no
appreciable levels of CC3 in tumors from mice not sup-
plemented with leucine; however, leucine supplementation
in both the control and CR diet groups resulted in marked
CC3-positive areas (n = 5/group; P <0.05) (Figure 2B).
Leucine supplementation in the CR group resulted in
much higher levels of apoptosis with 9.8 percent of the
tumor composed of apoptotic areas in the CR group com-
pared to 1.6 percent in the control group (Figure 2B). This
increase in apoptosis could explain why leucine supple-
mentation in the CR group, despite an equivalent level ofand apoptosis. (A) Differences in tumor volume between mice on
plementation 4 weeks after tumor cell injections (control, control +
and both leucine-supplemented groups; P <0.001 between all other
lyses performed on tumor sections for Ki-67 (n = 5/group; P <0.001
5/group; P <0.01 between the two leucine-supplemented groups;
t 200 μm. Tumor volume is presented as mean ± SD, and Ki-67 and
ant if P <0.05. Abbreviations: CON, control diet; CR,calorie restriction
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tumor growth. Although apoptosis occurred in tumors of
mice that consumed leucine-supplemented diets, 0.3 mM
leucine supplementation in vitro did not significantly
affect CC3 levels (Additional file 2) due to 1% FBS only
partially modeling CR through growth factor reduction.
CR and leucine supplementation have differential effects
on energy responsive signaling intermediates
The effects of energy balance and leucine supplementation
on mTOR signaling were assessed by immunohisto-
chemical analyses of the levels of phospho (p)-mTOR,
p-ACC (a marker of AMPK activity, an upstream inhibitor
of mTOR), and p-S6 and cyclin D1 (both downstream
mTOR targets). Based on this analysis, we found that
tumors from CR mice without leucine supplementation,Figure 3 Effects of calorie restriction (CR) and/or leucine (LEU) supple
Comparison of immunohistochemical analyses on tumor sections for phos
(P <0.001 between control and CR; P <0.01 between control + LEU and CR;
groups with different letters), phospho-ACC (P <0.05 between the two leuc
different letters) (n = 5/group). Scale bars represent 200 μm. All data are pre
if P <0.05. Abbreviations: CON, control diet; CR,calorie restriction diet; LEU, lrelative to tumors from control mice without leucine
supplementation, displayed increased levels of p-ACC
(n = 5/group; P <0.05) and reduced levels of p-mTOR
(n = 5/group; P <0.05) and its downstream effector, p-S6
ribosomal protein (n = 5/group; P <0.001). Additionally,
tumors from CR mice, relative to tumors from control
mice, showed significantly reduced levels of cyclin D1
(n = 5/group; P <0.05) (Figure 3A).
Leucine supplementation in the control diet did not
significantly alter amounts of these energy responsive
intermediates. However, leucine supplementation in
the CR diet significantly reduced p-ACC (n = 5/group;
P <0.001) and increased p-mTOR (n = 5/group; P <0.05),
p-S6 (n = 5/group; P <0.05), and cyclin D1 (n = 5/group;
P <0.05) to levels comparable to the nonsupplemented
control group (Figure 3A-B).mentation on energy responsive signals in Panc02 tumors. (A)
pho-mTOR (P <0.05 between groups with different letters), phospho-S6
P <0.05 between CR and CR + LEU), cyclin D1 (P <0.05 between
ine-supplemented groups; P <0.001 between all other groups with
sented as the mean ± SEM. Differences are considered significant
eucine-supplemented diet.
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To confirm the proliferative effect of leucine supplementa-
tion seen in vivo, in vitro analyses were performed using
the Panc02 cell line. To model the growth factor restrict-
ive environment in CR mice relative to the overweight
control mice as seen in Figure 1H, we grew the cells in
media with either 1% FBS or 10% FBS. Supplementing
media with 1% FBS has been used to mimic serum growth
factor reduction found in calorie-restricted mice [33]. In
the growth factor-rich environment of media with 10%
FBS, cell viability was significantly increased by ~30% with
0.3 mM leucine supplementation (P <0.05) (Figure 4A).
Leucine supplementation also increased cell viability
by ~30% in the growth factor-restricted environment
of media with 1% FBS (P <0.01) (Figure 4B). These
30% increases are similar to the increases in Ki-67
seen when comparing mice on leucine-supplemented
diets to their respective nonsupplemented controls
(Figure 2B). This 0.3 mM concentration of leucine were
chosen based on experiments showing that: i) serum leu-
cine increased by 0.3 mM in mice consuming a leucine-
supplemented diet [34]; and ii) cell viability of Panc02 cells
significantly increased with 0.3 mM leucine supplementa-
tion in vitro (Additional file 3).
Effect of leucine supplementation on mTOR pathway
intermediates
In order to understand the differential response to
leucine supplementation between the diet groups with re-
spect to mTOR signaling, in vitro analyses were performed
using Panc02 cell lines. Western blot analyses for the en-
ergy responsive intermediates p-AMPK, p-ACC, p-mTOR,
p-p70S6K, and p-S6 revealed that the effects of leucine
supplementation on cell signaling intermediates were im-
pacted by growth factor availability. In the growth factor-
rich environment of media with 10% FBS, supplementation
with 0.3 mM leucine had no effect on phosphorylatedA
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Figure 4 Effects of leucine supplementation on viability of Panc02 tu
media with either (A) 10% fetal bovine serum (FBS) or (B) 1% FBS as assess
(* = P <0.05, ** = P <0.01). All data are presented as the mean ± SEM. DiffereAMPK, ACC, mTOR, p70S6K, or S6 ribosomal protein
(Figure 5A,B). In the 1% FBS setting, leucine supplementa-
tion had no effect on phosphorylated AMPK or ACC,
but did significantly increase phosphorylated mTOR
(P <0.05) and its downstream effector S6 ribosomal
protein (P <0.05). Another downstream effector of mTOR,
p-p70S6K, was also increased with leucine supplementa-
tion in the 1% FBS setting, although the difference was
not statistically significant (Figure 5A,C).
Discussion
Findings in this report demonstrate for the first time
that dietary leucine supplementation increases growth of
pancreatic tumors. More specifically, we show that leu-
cine supplementation not only enhances the protumori-
genic nature of a high calorie, high carbohydrate control
diet, but also partially overcomes the well-established
anticancer effects of CR. The mechanisms underlying
these leucine-induced protumor effects may be diet-
dependent, suggested by increased glucose availability in
overweight mice and increased activation of the mTOR
protein synthetic pathway in CR mice.
Mice administered the leucine-supplemented control
diet developed the largest tumors and had the highest
level of tumor cell proliferation of all four groups.
The increased tumor burden observed in the leucine-
supplemented control group (relative to controls without
leucine supplementation) occurred without significant
changes in tumoral apoptosis or mTOR activation, as
evidenced by unchanged levels of both p-AMPK, an
upstream inhibitor of mTOR, and p-S6, a downstream
effector of mTOR. In overweight control mice, high basal
levels of circulating IGF-1 and tumoral mTOR activity are
consistently found [10]. This high level of activity likely
blunted any further increase in mTOR activation in
response to leucine supplementation in the control diet,
suggesting a biological threshold was attained. ThisB
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mor cells. (A-B) Comparison of relative viability of cells grown in
ed by MTT assays after 48 hours of 0.3 mM leucine supplementation
nces are considered significant if P <0.05.
Figure 5 Effects of leucine supplementation on energy responsive signals of Panc02 tumor cells. (A-C) Western blot analysis of
phosphorylated AMPK, ACC, mTOR, p70S6K, and S6 after 20 minutes of 0.3 mM leucine administration after pretreatment with respective media
for 3 hours. Data shown are representative blots from three biological replicates, and images for each protein are from the same blot. (B-C)
Relative phosphorylation of p-AMPK, p-ACC, p-mTOR, p-p70S6K, and p-S6 in cells grown in media with either (A) 10% FBS or (B) 1% FBS with or
without leucine supplementation (* = P <0.05). All data are presented as the mean ± SEM. Differences are considered significant if P <0.05.
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ation was substantiated using Panc02 cancer cells in vitro,
because mTOR activation was only enhanced in response
to leucine under growth factor restrictive conditions
(1% FBS) and not growth factor-abundant conditions
(10% FBS). The enhanced tumor growth in the leucine-
supplemented control group cannot be explained bychanges in mTOR signaling in the tumor, but was associ-
ated with greater glucose availability (reduced fasting insu-
lin levels and diminished glucose clearance). High levels of
glucose have been shown to increase proliferation in mul-
tiple pancreatic cancer cell lines by stimulating glucose
consumption and metabolism [35,36]. Although the noted
effects on insulin levels in the control group contradict
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secretagogue and enhancer of blood glucose disposal in
patients with type 2 diabetes [37], recent evidence sug-
gests that leucine’s effects on glucose sensitivity differ
depending on physiologic context, i.e., diabetic versus
non-diabetic state [38]. In a physiologic scenario, leucine
stimulates mTOR activity in the β-cells of the pancreas
and promotes proliferation and thus insulin secretion
[38]. On the other hand, chronic β-cell hyperfunction, a
consequence of excessive leucine exposure, results in
accelerated β-cell apoptosis and eventual secretory defi-
ciency through a negative feedback loop involving the
mTOR-dependent inhibition of IRS-1 [39]. Indeed, a diet
consisting of high levels of leucine combined with satu-
rated fatty acids results in insulin resistance in rodents
[40], and chronic infusion of amino acids at high concen-
trations induces insulin resistance in humans [41]. Leucine
supplementation did not induce insulin resistance in mice
on the CR regimen. CR has been shown to decrease basal
p70S6K activation, which may have protected against
mTOR-dependent β-cell hyperfunction [40]. Taken to-
gether, our data suggest that control tumors obtained a
leucine-induced growth advantage because of increased
glucose availability as a consequence of either impaired
insulin secretion or function.
Mice administered the CR diet without leucine sup-
plementation had the smallest tumors and lowest level
of tumor cell proliferation, while mice fed the leucine-
supplemented CR regimen (relative to CR mice without
leucine supplementation) had increased tumor growth
to levels intermediate between the unsupplemented mice
on the CR and control diets. Leucine supplementation
in the CR diet, relative to CR alone, also increased
tumor cell proliferation (to the levels observed in control
mice), and increased apoptosis. It is not uncommon to
observe increases in both cell proliferation and cell death
in the same tumor, as seen in the tumors of mice on the
CR diet. In fact, a number of dominant oncogenes
that increase proliferation through induction of aberrant
growth signals, also induce apoptosis [42]. Thus, leucine-
induced dysregulation of growth signals, such as mTOR
activation, in a setting of low-energy substrates and
growth factors in response to a CR regimen, may explain
the observed increases in apoptosis, tumor cell prolifera-
tion (to control levels), and partial rescue of tumor burden
in the leucine-supplemented CR mice. This rescue of
tumor burden was only partial, because leucine signifi-
cantly increased proliferation. As previously stated, high
levels of mTOR activity support proliferation and survival
of pancreatic cancer cells, and CR consistently results in
decreased activation of mTOR in pancreatic tumors [13].
In contrast to tumors from the leucine-supplemented
control group, we found that tumors from the leucine-
supplemented CR group demonstrated marked increasesin mTOR activation, as evidenced by lower levels of p-
AMPK and higher levels of p-S6 and cyclin D1, without
changes in fasting insulin levels and glucose clearance.
The maintenance of physiologic insulin secretion in the
CR mice was perhaps due to the protection of β-cells by
chronic CR, a strategy that has been shown to in-
crease β-cell proliferation in rats [43]. Taken together,
our data suggest that CR tumors obtained a leucine-
induced growth advantage because of increased mTOR
activation.
Conclusions
This report establishes that dietary leucine supplementa-
tion, irrespective of energy balance status, promotes
pancreatic tumor growth. These findings suggest caution
regarding the clinical use of leucine supplementation for
purposes of lean muscle enhancement in cachectic can-
cer patients. Additional research is needed to ascertain
the impact amino acids (BC or otherwise) have on cancer
growth and muscle repair; the identification of mTOR-
independent approaches to spare muscle in cachectic
cancer patients; and the link between energy balance,
mTOR signaling, and amino acid metabolism.
Additional files
Additional file 1: Effects of leucine supplementation on glucose
tolerance at 6 weeks. Glucose tolerance test (GTT) performed after
6 weeks on diet (n = 10/group; P <0.001 between control with leucine
supplementation and the calorie restriction (CR) groups; P <0.05 between
the control groups). All data are presented as the mean ± SEM.
Differences are considered significant if P <0.05.
Additional file 2: Effects of single BCAA supplementation on
apoptosis of Panc02 tumor cells. Western blot analysis of cleaved
caspase-3 protein levels after 24 hours of either 0.3 mM leucine, isoleucine,
or valine administration. Data shown are representative blots from three
biological replicates. Relative protein levels of cleaved caspase-3 were
quantified by densitometry using LI-COR Odyssey software. All data are
presented as the mean ± SEM. Differences are considered significant if
P <0.05.
Additional file 3: Effects of different doses of leucine
supplementation on Panc02 tumor cell viability. Comparison of
relative cell viability as assessed by MTT assays after 48 hours of leucine
supplementation (* = P <0.05). All data are presented as the mean ± SEM.
Differences are considered significant if P <0.05.
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